Purespring Therapeutics to appoint Richard Francis as CEO

pharmafile | January 11, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Purespring Therapeutics, a kidney-focused AAV gene therapy company, has announced it will appoint Richard Francis as Chief Executive Officer from February this year.

Francis is a pharmaceutical executive with over 25 years’ experience in building sustainable, world-class life science companies. He most recently held the role of Chief Executive Officer of Sandoz, a division of Novartis, and was also a member of the Novartis Executive Committee. Richard joined Novartis from Biogen Idec, where he held global and country leadership positions during his 13-year career with the company. He has also worked at Sanofi-Synthelabo and Wyeth, where he held various commercial roles.

In addition to his full-time role as Chief Executive of Purespring, Richard will spend part of his time as a Partner at Syncona Investment Management Limited, providing valuable advice and commercial and operational expertise across the Syncona portfolio.

Francis himself said: “I am delighted to be joining Purespring at the beginning of this exciting journey and to be building a world class gene therapy company. I was attracted to Purespring because of the strength of the science and the world-class founding team who are leading experts in the kidney and gene therapy fields.

“Purespring will be an agile, dynamic company that focuses on building a talented team that truly wants to make a difference to the millions of people suffering from kidney related diseases.”

Related Content

No items found

Latest content